To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
Arthritis, Polymyalgia Rheumatica, Immune Checkpoint Inhibitors
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
-
MD Anderson Cancer Center, Houston, Texas, United States, 77030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
M.D. Anderson Cancer Center,
Y. Jeff Li, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center
2028-03-31